ArticleFrontiers in pharmacology2026
Anxiolytic and antidepressant effects of astaxanthin: behavioral and mechanistic insights in a rat model.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Astaxanthin (AST) is a potent carotenoid with antioxidant properties that has garnered attention for its potential neuropharmacological effects. Purpose: This study investigates the anxiolytic and antidepressant activities of AST in a rat model to elucidate its therapeutic potential for mood disorders. Material and Methods: Fifty-four male rats were divided into nine groups receiving normal saline, astaxanthin (AST, 5, 10, and 15 mg/kg), diazepam (DZP, 0.5 mg/kg), fluoxetine (FXT, 5 mg/kg), or combinations of AST (10 mg/kg) with receptor antagonists flumazenil (FLU, GABA-A antagonist), atropine (ATR, muscarinic antagonist), and naloxone (NAL, opioid antagonist) for 14 consecutive days. At the end of the study, behavioral assessments were conducted, including the open field, light-dark box, elevated plus maze, tail suspension, and forced swimming tests. Biochemical analyses were performed to evaluate serum catalase (CAT), glutathione (GSH), nitrite, and matrix metalloproteinase-2 (MMP-2) and MMP-9 activities. Results and Discussion: Astaxanthin, particularly at 10 mg/kg, significantly reduced anxiety- and depressive-like behaviors, comparable to DZP and FXT in four-week-old male Wistar rats. Pretreatment with FLU, ATR, or NAL partially reversed these effects, suggesting involvement of GABAergic, cholinergic, and opioid pathways. Furthermore, AST enhanced antioxidant defenses, evidenced by increased serum CAT and GSH levels and reduced nitrite concentrations. Gelatin zymography revealed that AST increased MMP-2 activity while slightly decreasing MMP-9 activity, a partial reversal by the aforementioned antagonists. Conclusion: The results suggest that AST could produce anxiolytic and antidepressant effects. Such effects are likely mediated through GABAergic, cholinergic, and opioid systems, as well as antioxidant and anti-inflammatory mechanisms. Future studies should focus on well-controlled clinical trials to evaluate the preclinical results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.